about
Mutations in SLC39A14 disrupt manganese homeostasis and cause childhood-onset parkinsonism-dystoniaSmall molecule induced reactivation of mutant p53 in cancer cellsA first generation inhibitor of human Greatwall kinase, enabled by structural and functional characterisation of a minimal kinase domain constructA synthetic, catalytic and theoretical investigation of an unsymmetrical SCN pincer palladacycleHarnessing Fluorine-Sulfur Contacts and Multipolar Interactions for the Design of p53 Mutant Y220C Rescue DrugsMicrowave-mediated synthesis of an arylboronate library.Synthesis and biological evaluation of 1,4-benzodiazepin-2-ones with antitrypanosomal activity.Research spotlight: Microwave chemistry enabling the synthesis of biologically relevant amines.Synthesis and Biological Evaluation of JAHAs: Ferrocene-Based Histone Deacetylase Inhibitors.Identification and development of the 1,4-benzodiazepin-2-one and quinazoline-2,4-dione scaffolds as submicromolar inhibitors of HAT.The potential of palladacycles: more than just precatalysts.Synthesis and solid-state characterisation of 4-substituted methylidene oxindoles.A ruthenium anticancer compound interacts with histones and impacts differently on epigenetic and death pathways compared to cisplatin.Recent advances in the development of selective CB(2) agonists as promising anti-inflammatory agents.Achiral, selective CCK2 receptor antagonists based on a 1,3,5-benzotriazepine-2,4-dione template.Optimization of 1,3,4-benzotriazepine-based CCK(2) antagonists to obtain potent, orally active inhibitors of gastrin-mediated gastric acid secretion.Novel, achiral 1,3,4-benzotriazepine analogues of 1,4-benzodiazepine-based CCK(2) antagonists that display high selectivity over CCK(1) receptors.The Histone Deacetylase Inhibitor JAHA Down-Regulates pERK and Global DNA Methylation in MDA-MB231 Breast Cancer Cells.Cytotoxicity of the Urokinase-Plasminogen Activator Inhibitor Carbamimidothioic Acid (4-Boronophenyl) Methyl Ester Hydrobromide (BC-11) on Triple-Negative MDA-MB231 Breast Cancer Cells.A cyclodextrin-capped histone deacetylase inhibitor.Excellent correlation between cathepsin B inhibition and cytotoxicity for a series of palladacycles.Synthesis of a 1,4-benzodiazepine containing palladacycle with in vitro anticancer and cathepsin B activity.Structural and biological investigation of ferrocene-substituted 3-methylidene-1,3-dihydro-2H-indol-2-ones.Exploiting Transient Protein States for the Design of Small-Molecule Stabilizers of Mutant p53.Synthesis of Functionalized Hydrazines: Facile Homogeneous (N-Heterocyclic Carbene)-Palladium(0)-Catalyzed Diboration and Silaboration of Azobenzenes.Biological Effect of a Hybrid Anticancer Agent Based on Kinase and Histone Deacetylase Inhibitors on Triple-Negative (MDA-MB231) Breast Cancer Cells.Synthesis of an [(NHC)2 Pd(SiMe3 )2 ] Complex and Catalytic cis-Bis(silyl)ations of Alkynes with Unactivated Disilanes.Seven 3-methylidene-1H-indol-2(3H)-ones related to the multiple-receptor tyrosine kinase inhibitor sunitinib.Prodrug and covalent linker strategies for the solubilization of dual-action antioxidants/iron chelators.Synthesis of kinase inhibitors containing a pentafluorosulfanyl moiety.Highlights from SelectBio 2015: Academic Drug Discovery Conference, Cambridge, UK, 19-20 May 2015.Molecular Signatures Associated with Treatment of Triple-Negative MDA-MB231 Breast Cancer Cells with Histone Deacetylase Inhibitors JAHA and SAHA.Seizure control by derivatives of medium chain fatty acids associated with the ketogenic diet show novel branching-point structure for enhanced potency.Carbon dots (C-dots) from cow manure with impressive subcellular selectivity tuned by simple chemical modification.Boron medicinal chemistry and synthetic aspects.G-protein coupled receptor and kinase targets: advances in drug discovery from molecular to clinical.Welcome to 'microwaves in medicinal chemistry'.Elaboration of tetra-orthogonally-substituted aromatic scaffolds towards novel EGFR-kinase inhibitors.Cytotoxic effects of Jay Amin hydroxamic acid (JAHA), a ferrocene-based class I histone deacetylase inhibitor, on triple-negative MDA-MB231 breast cancer cells.Synthesis and evaluation of metallocene containing methylidene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors.
P50
Q27316540-28EC8408-16D4-4013-8C96-F4E3E4CC32D0Q27677872-DD75871B-DEC5-4582-BAA6-1039C2EE3D9BQ27727741-236729BA-EB01-439B-9FE8-81210749621EQ28603481-F5478E34-112B-45DC-B9E0-708BE7BFF2A0Q28829378-436F7C69-BECE-4833-8E30-A17C9D6CC4C3Q33797146-A935587C-7B5C-427A-B6D2-0C1277388369Q33816494-B0608863-22F3-4BE2-93F3-65D0416FC6DCQ33852484-62DA22E7-5460-4B0C-AC98-905603DA8CD2Q33900124-A04F8E99-87A2-463E-93FC-9597C1ED162CQ34417029-7717A4FC-6F1F-48F3-A089-644182AE4A8AQ36154668-1FD92FE6-E827-4278-A4EE-9DCC0B6662FBQ37425603-8FFE76FD-622B-42DC-84A5-E6B66BC58E19Q37709331-73C68CA8-8A74-4198-8B36-DB7CFE22D583Q38019601-9B8C1B02-E64E-478F-B111-49B1EE9B8346Q38502210-4AA82C29-A7F1-4369-80AD-CA519091E537Q38505724-3BDEFBBE-4DB7-42D0-A5AF-BB3A86E6621BQ38510673-0943B497-3FD1-4D90-B39C-9E48FA51E1B8Q38631950-8FB6C9FC-8243-4478-8AAB-7D197F199D75Q38869026-C780F2A3-91E6-41E7-BD30-A1D4F04DD0C1Q39165390-97621ACF-C088-4F56-811D-E2888403B06FQ39761130-8E33260C-9BA9-4EDF-82EA-1A6388E8BA08Q39815619-D88F8F60-8306-4009-BDAD-3A599DF1BC31Q39890365-DF3A7A37-6F53-4917-8F08-7127C6E5DFAEQ40242926-D64F3DA4-BC1B-4B47-A7EB-49813FD25462Q40817997-1C8BE2E7-F39C-45C6-954A-13F8446CAC94Q40952382-28068FDE-2FEF-4663-853E-4B2DAF66EF27Q41379905-B699E7F4-F00E-4B64-9488-6AB929A03421Q43177335-B1B2E0FB-BB3B-4B3C-A147-73D2B4780211Q44188874-F1F1E4FA-ABEB-450B-884D-1949C9BE677DQ47116598-1EDCACCE-925C-4669-9F24-30FDA99B2678Q47997537-9FDE958B-DFC1-4729-ABE5-130147E09B21Q48319950-63F68437-4427-4688-9AE0-F17D8E8D7AC8Q48481486-B59B4DD5-845F-41B3-BDF8-7198798C0267Q50439243-76E475C5-F01F-4D98-9298-24A4F6902830Q51449258-4C902F3C-CF7D-4A00-8882-0DD4F3983656Q51690191-5A5BCE53-36F4-4862-9225-B43D7B4B3177Q51720998-7C0B1CE3-A7EE-4E05-AACD-427C43770BD2Q51736886-DE6178FE-640F-41B6-BAFF-83EF0D069E07Q53137642-011EE43E-308E-462F-904B-6443332FD0E5Q54609190-A9911356-8E9E-4ABD-B306-7C665BC97A66
P50
description
biochemist
@en
wetenschapper
@nl
name
John Spencer
@ast
John Spencer
@en
John Spencer
@es
John Spencer
@nl
John Spencer
@sl
type
label
John Spencer
@ast
John Spencer
@en
John Spencer
@es
John Spencer
@nl
John Spencer
@sl
altLabel
John Spencer
@en
prefLabel
John Spencer
@ast
John Spencer
@en
John Spencer
@es
John Spencer
@nl
John Spencer
@sl
P1053
C-2156-2008
P106
P31
P3829
P496
0000-0001-5231-8836